Terms: = Ovarian cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Prognosis
51 results:
1. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
2. Role of gene sequencing in classifying struma ovarii: braf p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic value of ALK overexpression and molecular abnormalities in high-grade serous ovarian carcinoma.
Gorczyński A; Miszewski K; Gager Y; Koch S; Pötschke J; Ugrinovski D; Gabert J; Pospieszyńska A; Wydra D; Duchnowska R; Szymanowski B; Cierniak S; Kruecken I; Neumann K; Mirkov K; Biernat W; Czapiewski P
Cancer Biomark; 2023; 38(1):17-26. PubMed ID: 37522200
[TBL] [Abstract] [Full Text] [Related]
4. Association of UBE2L6 and ABCB6 Expression With Platinum Resistance in Serous ovarian Carcinoma.
Shibahara M; Kurita T; Murakami M; Harada H; Koi C; Izumi H; Yoshino K
Anticancer Res; 2023 Aug; 43(8):3787-3792. PubMed ID: 37500176
[TBL] [Abstract] [Full Text] [Related]
5. The highs and lows of serous ovarian cancer.
Grisham RN; Manning-Geist BL; Chui MH
Cancer; 2023 Sep; 129(17):2613-2620. PubMed ID: 37366225
[TBL] [Abstract] [Full Text] [Related]
6. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Thomson JP; Hollis RL; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Nussey F; Lok C; Herrington CS; Gourley C
Gynecol Oncol; 2023 Jul; 174():157-166. PubMed ID: 37207500
[TBL] [Abstract] [Full Text] [Related]
7. CT-based machine learning radiomics predicts CCR5 expression level and survival in ovarian cancer.
Wan S; Zhou T; Che R; Li Y; Peng J; Wu Y; Gu S; Cheng J; Hua X
J Ovarian Res; 2023 Jan; 16(1):1. PubMed ID: 36597144
[TBL] [Abstract] [Full Text] [Related]
8. Low-grade serous carcinoma detected from intraoperative peritoneal washings: Cytological findings and detection of KRAS mutation.
Yamamoto E; Warigaya K; Kinoshita Y; Yamamoto A; Murata SI
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1676. PubMed ID: 35801373
[TBL] [Abstract] [Full Text] [Related]
9. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
[TBL] [Abstract] [Full Text] [Related]
10. [Effect of RBP2 gene silencing on proliferation, migration and invasion of ovarian epithelial cancer SKOV3/DDP cells and its mechanism].
Feng TF; Yao DM; Zheng R; Jiang DS; Zhang LL; Xing Q; Li L
Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):139-146. PubMed ID: 35184457
[No Abstract] [Full Text] [Related]
11. Nomogram of Combining CT-Based Body Composition Analyses and Prognostic Inflammation Score: Prediction of Survival in Advanced Epithelial ovarian cancer Patients.
Wang X; Zhang C; Cao F; Wang CB; Dong JN; Wang ZH
Acad Radiol; 2022 Sep; 29(9):1394-1403. PubMed ID: 34955366
[TBL] [Abstract] [Full Text] [Related]
12. Spectrum of
Chui MH; Chang JC; Zhang Y; Zehir A; Schram AM; Konner J; Drilon AE; Da Cruz Paula A; Weigelt B; Grisham RN
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568720
[TBL] [Abstract] [Full Text] [Related]
13. RAD51AP1 Loss Attenuates Colorectal cancer Stem Cell Renewal and Sensitizes to Chemotherapy.
Bridges AE; Ramachandran S; Tamizhmani K; Parwal U; Lester A; Rajpurohit P; Morera DS; Hasanali SL; Arjunan P; Jedeja RN; Patel N; Martin PM; Korkaya H; Singh N; Manicassamy S; Prasad PD; Lokeshwar VB; Lokeshwar BL; Ganapathy V; Thangaraju M
Mol Cancer Res; 2021 Sep; 19(9):1486-1497. PubMed ID: 34099522
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic and Theranostic Biomarkers in ovarian Clear Cell Carcinoma.
Wiedemeyer K; Wang L; Kang EY; Liu S; Ou Y; Kelemen LE; Feil L; Anglesio MS; Glaze S; Ghatage P; Nelson GS; Köbel M
Int J Gynecol Pathol; 2022 Mar; 41(2):168-179. PubMed ID: 33770057
[TBL] [Abstract] [Full Text] [Related]
15. Population-based estimates of survival among elderly patients with brain metastases.
Lamba N; Kearney RB; Catalano PJ; Hassett MJ; Wen PY; Haas-Kogan DA; Aizer AA
Neuro Oncol; 2021 Apr; 23(4):661-676. PubMed ID: 33068418
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
Nilforoushan N; Moatamed NA
Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
[TBL] [Abstract] [Full Text] [Related]
17. RAS Mutation in Mucinous Carcinoma of the Ovary.
Panyavaranant P; Teerapakpinyo C; Pohthipornthawat N; Oranratanaphan S; Shuangshoti S; Triratanachat S
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1127-1132. PubMed ID: 31030485
[TBL] [Abstract] [Full Text] [Related]
18. Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
Yano M; Asami Y; Nishikawa T; Yoshida S; Kamada K; Katoh T; Teramoto Y; Nakamura Y; Yasuda M
Medicine (Baltimore); 2018 Oct; 97(43):e12937. PubMed ID: 30412106
[TBL] [Abstract] [Full Text] [Related]
19. Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
Jin M; Cai J; Wang X; Zhang T; Zhao Y
Cancer Biol Ther; 2018; 19(12):1088-1092. PubMed ID: 30110192
[TBL] [Abstract] [Full Text] [Related]
20. Paediatric diffuse leptomeningeal tumor with glial and neuronal differentiation harbouring chromosome 1p/19q co-deletion and H3.3 K27M mutation: unusual molecular profile and its therapeutic implications.
Nambirajan A; Suri V; Kedia S; Goyal K; Malgulwar PB; Khanna G; Panda PK; Gulati S; Garg A; Sharma MC
Brain Tumor Pathol; 2018 Jul; 35(3):186-191. PubMed ID: 30030640
[TBL] [Abstract] [Full Text] [Related]
[Next]
